Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Mersana Therapeutics Announces Additional Fda Fast Track Designation Granted To Emiltatug Ledadotin Xmt 1660 is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Mersana Therapeutics Announces Additional FDA Fast Track Designation ...
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660) ... Read More
Mersana Therapeutics Announces Additional FDA Fast Track Designation ...
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660) Jan. 10, 2025 6:02 AM ET Mersana Therapeutics, Inc. (MRSN) GlobeNewswire ... Read More
Mersana Therapeutics Receives Additional FDA Fast Track Designation for ...
Mersana Therapeutics, Inc. announced that the FDA has granted an additional Fast Track designation for its drug XMT-1660, also known as emiltatug ledadotin (Emi-Le), aimed at treating advanced or ... Read More
Mersana Therapeutics Announces Additional FDA Fast Track Designation ...
CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ... Read More
Mersana Therapeutics: FDA grants additional Fast Track designation to ...
Mersana Therapeutics (MRSN) announced the U.S. FDA recently granted an additional Fast Track designation to XMT-1660. The company also announced that the World Health Organization has approved ... Read More
Mersana Therapeutics Announces Additional FDA Fast Track Designation ...
Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ETCAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus